JP2006096745A - Health function-improving agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a health function-improving agent which can be taken for long periods. <P>SOLUTION: This health function-improving agent contains a δ-amino acid, its derivative or its salt as an active ingredient. Preferably, the health function-improving agent is characterized by improving motor functions to improve the health functions. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a health function improving agent.

  Human and animal health functions are reduced by fatigue, illness, pregnancy, aging, malnutrition, and nutritional deficiencies. This fatigue includes physical fatigue and mental fatigue, and not only physical fatigue but also mental fatigue is greatly involved in modern human fatigue.

Among these, as a nutrient effective for physical fatigue, complex carbohydrates such as sugar and starch are used. Further, vitamin B ₁ , vitamin B ₂ , vitamin B group such as nicotinic acid, melatonin, vitamin C, vitamin E, magnesium and the like are used as drugs.

Recently, it has been reported that amino acids having a specific composition including essential amino acids and non-essential amino acids have an effect of improving motor function during fatigue (Patent Document 1). Essential amino acids include valine, leucine, isoleucine, lysine, threonine, and methionine. Non-essential amino acids include arginine, glutamine, and proline.
Japanese Patent Laid-Open No. 9-249556

However, among the amino acids, glutamine has low solubility and is unstable and has the problem of breaking down into glutamate and ammonia in the body, and arginine has side effects such as rough skin, thick skin, joint enlargement, and bone malformation. It is known that there is a great deal of caution regarding its consumption.
Accordingly, an object of the present invention is to provide a health function improving agent that can be taken for a long time.

Therefore, the present inventor has examined the pharmacological action of various amino acids, and found that δ-amino acids represented by 5-aminolevulinic acid have an action of significantly increasing the health function of an aged animal in particular. The headline and the present invention were completed.
That is, this invention provides the health function improving agent which uses (delta) -amino acid, its derivative (s), or its salt as an active ingredient.

  ADVANTAGE OF THE INVENTION According to this invention, the health function of the animal which the health function fell, for example, the animal containing the person whose health function fell with aging can be improved.

  The active ingredient of the health function improving agent of the present invention is a δ-amino acid, a derivative thereof or a salt thereof. The δ-amino acids include the following formula (1)

(Wherein R ¹ represents a hydrogen atom or an acyl group, and R ² represents a hydrogen atom or a hydrocarbon group which may have a substituent)
And a derivative thereof or a salt thereof (hereinafter referred to as “5-aminolevulinic acid”).

  The 5-aminolevulinic acids are photosensitizers in photodynamic therapy (Japanese Patent Publication No. 2004-505105), plant growth regulators (JP 07-53487 A), herbicides (JP 05-117110 A), It is known to be useful as fish pathogenic microorganisms, parasitic infection treatment (Japanese Patent Laid-Open No. 2001-316255), pig growth promoter (Japanese Patent Laid-Open No. 2003-40770) and the like.

In formula (1), examples of the acyl group represented by R ¹ include an alkanoyl group having 1 to 24 carbon atoms, an aromatic acyl group, and a benzyloxycarbonyl group. Specific examples of preferable acyl groups include acetyl group, n-propanoyl group, n-butanoyl group, n-pentanoyl group, n-hexanoyl group, n-nonanoyl group, benzyloxycarbonyl group and the like. Among these, a C1-C6 alkanoyl group is more preferable.

Examples of the hydrocarbon group optionally having a substituent represented by R ² include a group selected from hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo, fluoro, chloro and nitro. The hydrocarbon group which may be substituted is shown. Here, the hydrocarbon group is preferably an alkyl group, an alkenyl group, an aralkyl group or an aryl group. Here, as an alkyl group, a linear, branched or cyclic alkyl group is mentioned, A C1-C40, Furthermore, a 1-18, especially 1-7 alkyl group is preferable. Examples of the alkenyl group include linear, branched or cyclic alkenyl groups, and alkenyl groups having 2 to 40 carbon atoms and more preferably 2 to 18 carbon atoms are preferable. Examples of the aralkyl group include those composed of an aryl group having 6 to 20 carbon atoms and an alkyl group having 1 to 6 carbon atoms. Moreover, as an aryl group, a C6-C20 aryl group is mentioned.
As an alkoxy group, a C1-C18 alkoxy group, especially a C1-C7 alkoxy group are preferable. The acyloxy group is preferably an alkanoyloxy group having 1 to 18 carbon atoms, particularly an alkanoyloxy group having 2 to 8 carbon atoms. As the alkoxycarbonyloxy group, a C _1-18 alkoxy-carbonyloxy group, particularly a C _1-7 alkoxy-carbonyloxy group is preferable.
Preferred examples of the alkyl group having 1 to 18 carbon atoms include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, isopentyl group, and neopentyl group. Tert-pentyl group, 2-methylbutyl group, n-hexyl group, isohexyl group, 3-methylpentyl group, ethylbutyl group, n-heptyl group, 2-methylhexyl group, n-octyl group, isooctyl group, tert-octyl group Group, 2-ethylhexyl group, 3-methylheptyl group, n-nonyl group, isononyl group, 1-methyloctyl group, ethylheptyl group, n-decyl group, 1-methylnonyl group, n-undecyl group, 1,1- Dimethylnonyl group, n-dodecyl group, n-tridecyl group, n-tetradecyl group, n-pentadecyl group, - hexadecyl group, n- heptadecyl group, n- octadecyl group.
More preferable examples of the alkyl group having 1 to 7 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, and neopentyl. Group, tert-pentyl group, 2-methylbutyl group, n-hexyl group, isohexyl group, 3-methylpentyl group, ethylbutyl group, n-heptyl group and 2-methylhexyl group.
Examples of the alkyl group having 1 to 18 carbon atoms substituted by hydroxy include 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyhexyl and the like.
Examples of the C1- _C18 alkyl group substituted by alkoxy include C _1-7 alkoxy-C _1-18 alkyl groups such as 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 4 -Methoxybutyl, 4-ethoxybutyl, 2- (2-methoxyethyl) ethyl and the like.
Examples of the alkyl group substituted with an acyloxy group include a C _2-7 alkanoyloxy-C _1-18 alkyl group. Examples of the alkyl group substituted by an alkoxycarbonyloxy group include a C _1-18 alkoxy-carbonyloxy-C _1-18 alkyl group. Examples of the alkyl group substituted with an amino group include an amino-C _1-18 alkyl group.
Examples of the alkenyl group having 2 to 18 carbon atoms include vinyl group, allyl group, isopropenyl group, 2-butenyl group, 2-methylallyl group, 1,1-dimethylallyl group, 3-methyl-2-butenyl group, 3- Methyl-3-butenyl group, 4-pentenyl group, hexenyl group, octenyl group, nonenyl group, decenyl group, cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group, cycloheptenyl group, cyclooctenyl group, 4-methylcyclohexenyl Group, 4-ethylcyclohexenyl group, 2-cyclopentenylethyl group, cyclohexenylmethyl group, cycloheptenylmethyl group, 2-cyclobutenylethyl group, 2-cyclooctenylethyl group, 3- (4-methylcyclo Hexenyl) propyl group, 4-cyclopropenylbutyl group, 5- (4 Ethylcyclohexenyl) pentyl group, oleyl group, bacenyl group, linoleyl group, linolenyl group, trans-9-octadecenyl group, 9E, 12E-octadecadienyl group, 9E, 12E, 15E-octadecatrienyl group, etc. It is done.
The aralkyl group having 7 to 26 carbon atoms is preferably one composed of an alkyl group having 1 to 6 carbon atoms and an aryl group having 6 to 20 carbon atoms. Examples of the alkyl group having 1 to 6 carbon atoms include methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, tert-butyl group, n-pentyl group, n-hexyl group, A cyclopropyl group, a cyclobutyl group, a cyclohexyl group, etc. are mentioned, As a C6-C20 aryl group, a phenyl group, a naphthyl group, etc. are mentioned. Of the aralkyl groups having 7 to 26 carbon atoms, a benzyl group, a phenethyl group, and a 9-fluorenylmethyl group are preferable, and a benzyl group and a fluorenylmethyl group are particularly preferable. The aryl group of the aralkyl group has 1 to 6 carbon atoms such as the above-described alkyl group having 1 to 6 carbon atoms, methoxy group, ethoxy group, n-propoxy group, n-butoxy group, isobutoxy group, tert-butoxy group and the like. May be substituted by 1 to 3 substituents such as a carboxy group or a halogen atom such as an alkoxy group, a hydroxyl group, an amino group, a nitro group, a cyano group, fluorine, chlorine, bromine or iodine.
Examples of the aryl group having 6 to 20 carbon atoms include a phenyl group and a naphthyl group. For example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, C1-C6 alkyl group such as n-pentyl group, n-hexyl group, cyclopropyl group, cyclobutyl group, cyclohexyl group, methoxy group, ethoxy group, n-propoxy group, n-butoxy group, isobutoxy group, tert -Substituted by 1 to 3 substituents such as a C1-C6 alkoxy group such as a butoxy group, a hydroxyl group, an amino group, a nitro group, a cyano group, a halogen atom such as fluorine, chlorine, bromine or iodine, or a carboxy group It may be. R ¹ represents an amino group substituent, and R ² represents a carboxylic acid group substituent. These exemplified substituents are not only 5-aminolevulinic acids but also δ-amino acid substituents. But there is.

  Examples of the salt of δ-amino acid or a derivative thereof include hydrochloride, hydrobromide, hydroiodide, phosphate, methyl phosphate, ethyl phosphate, phosphite, hypophosphite, Nitrate, sulfate, acetate, propionate, toluenesulfonate, succinate, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate And acid addition salts such as fumarate, maleate and malate, and metal salts such as sodium salt, potassium salt and calcium salt, ammonium salt and alkylammonium salt. These salts are used as an aqueous solution or powder at the time of use.

  The above δ-amino acids, derivatives thereof or salts thereof may form hydrates or solvates, and any of them may be used alone or in combination of two or more.

δ-amino acids, derivatives thereof or salts thereof (hereinafter referred to as “δ-amino acids”) can be produced by any method of chemical synthesis, production by microorganisms, and production by enzymes. Among the δ-amino acids, 5-aminolevulinic acids are disclosed in JP-A-48-92328, JP-A-62-11954, JP-A-2-76841, JP-A-6-172281, It can be produced according to the methods described in Kaihei 7-188133, JP-A-11-42083, and the like. The δ-amino acids produced as described above, the chemical reaction solution and the fermentation solution before purification thereof can be used as they are without separation and purification as long as they do not contain harmful substances.
Moreover, a commercial item etc. can also be used.

  The δ-amino acids, as shown in the examples below, increase the amount of natural exercise in mice that have deteriorated in health function due to aging, and promote weight gain. It works to improve. In addition, δ-amino acids are liver function improvers and, as shown in Examples below, are administered orally to mice and act to reduce the γ-GTP value of mice. Therefore, the above-mentioned δ-amino acids are useful as an agent for improving the health function of animals including humans, and are particularly useful as an agent for improving the health function of animals including humans whose health functions have deteriorated due to aging.

  Moreover, the health-function improving agent of this invention can improve the effect further by containing a mineral or ingesting simultaneously. Examples of minerals include iron, zinc, copper, phosphorus, calcium, magnesium, potassium, selenium, chromium, manganese, iodine, boron, silicon, vanadium, molybdenum, cobalt, etc., particularly preferably iron, magnesium, manganese. is there. These mineral components can be used alone or in combination of two or more. Any chemical properties of minerals may be used as long as they do not harm the organism.

  A nutritional agent etc. can be added to the health function improving agent of this invention as needed. Examples of nutrients include essential amino acids, non-essential amino acids, vitamins, taurine, coenzyme Q10, alpha lipoic acid and other body factors, herbs, proteins, various enzymes, antioxidants such as polyphenols, and the like. Can be mentioned.

  The health function improver of the present invention adsorbs a powder of δ-amino acids, an aqueous solution in which δ-amino acids are dissolved in water, and a fermentation broth containing δ-amino acids produced by the above method to a carrier such as an excipient. It can also be used. As a kind of carrier, it may be a general one, crystalline cellulose, gelatin, starch, dextrin, oil cake, baker's yeast, brewer's yeast, liquor yeast, wine yeast, skim milk powder, lactose, animal and vegetable oils and fats, Anhydrous calcium phosphate, calcium carbonate, magnesium stearate, magnesium aluminate silicate, magnesium metasilicate aluminate and the like can be mentioned.

  Examples of the dosage form of the health function improving agent of the present invention include injections, tablets, capsules, fine granules, syrups, suppositories and the like. These can be produced according to a conventional method using a solvent, a dispersion medium, an extender, an excipient and the like as appropriate. Moreover, you may ingest as a form of food.

  When the health function improving agent of the present invention is prepared as an aqueous solution, when the δ-amino acids are 5-aminolevulinic acids, care should be taken so that the aqueous solution does not become alkaline in order to prevent decomposition of the active ingredient 5-aminolevulinic acids. There is a need to. When it becomes alkaline, decomposition of the active ingredient can be prevented by removing oxygen.

  The health function improving agent of the present invention is not limited as long as the health function can be improved by ingesting the agent, and the method of using the agent is not limited, but preferred embodiments are shown below.

  There are no particular limitations on the animal that is the target of the health function improver using this agent, but vertebrates such as mammals, reptiles, birds, amphibians, and fish are preferred. Examples of these include freshwater fish such as humans, cows, pigs, sheep, goats, mice, rats, rabbits, dogs, cats, chickens, salmon, rainbow trout, carp, eel, char, coho salmon, yellowtail, red sea bream, mackerel, tuna And marine ornamental fish such as tropical fish and reptiles.

  Although the use of this agent for improving the health function is possible at any time during the growth of the animal, humans are preferably 15 years old or later, and particularly preferably 35 years old or later.

  The method for ingesting the health function improving agent of the present invention is not particularly limited, and examples include oral ingestion, ingestion by ingestion, ingestion by tube, and ingestion by intestine, and oral ingestion is particularly preferable.

  This drug shows a sufficient effect even if it is taken once, but it can be taken multiple times to further enhance the effect. The effect per ingested agent is more effective when taken multiple times, and it is an efficient usage method to take a small amount every day.

  The amount of intake of this drug per 1 kg of the target animal is preferably 0.001 mg to 1000 mg, more preferably 0.001 mg to 100 mg, particularly preferably 0.001 mg to 50 mg as δ-amino acids. The intake of this drug should be increased as the period of growth increases and as the number of intakes decreases. Ingestion beyond the appropriate range is not desirable because it is not economical and can cause sun injury.

  Moreover, when using together minerals, you may use simultaneously and may use separately. The kind of mineral to be used, the method of using the same, and the amount of the mineral used may be the same as those of commercially available minerals. For example, in the case of iron, the amount of use may be 1 to 45 mg per day for an adult male, and 5 to 20 mg is preferable. In the case of magnesium, it may be 50 mg to 700 mg, preferably 100 to 500 mg. In the case of manganese, it may be 0.1 to 11 mg, preferably 2 to 8 mg.

  EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to this at all.

Example 1
Mice preliminarily raised for one week (35 to 45 weeks of age, BALB / cAJcl) were given 10 mg of 5-aminolevulinic acid (hereinafter referred to as ALA) hydrochloride per kg of mouse body weight once a day for 7 consecutive days. . ALA hydrochloride was adjusted to a concentration of 0.5 g / mL with distilled water and orally administered to mice. After the test, it was placed in a gauge having a floor area of 20 cm × 20 cm, and the moving distance for 5 minutes was measured. The test was carried out with 5 male mice and 5 female mice per group, for a total of 10 mice, and the values showed average values. In the section where ALA was treated, it was confirmed that the movement distance was large in both males and females and the exercise ability was improved. During the test, no abnormal symptoms such as abnormal excitement / behavior were observed in the mice treated with ALA.

Example 2
Aged retired mice (35-45 weeks old, BALB / cAJcl) preliminarily kept for 1 week were ingested 10 mg of ALA hydrochloride per kg of mouse body weight once a day for 7 consecutive days. ALA hydrochloride was adjusted to a concentration of 0.5 g / mL with distilled water and orally administered to mice. After the test, the mouse was dissected, the blood of the mouse was collected, ALA acid dehydrase (ALAD) activity per mL of blood (5-aminolevulinic acid was dimerized, and porphobilinogen, which is one molecule of pyrrole substance (hereinafter referred to as PBG). Activity) and porphobilinogen deaminase (PBGD) activity (activity for converting PBG to hydroxymethylbilane). The path where ALA forms PBG and the path from PBG to hydroxymethylbilane are some of the important paths for heme synthesis. After adding 0.33 mL of distilled water to 0.02 mL of heparinized mouse whole blood, 0.5 M Na-phosphate buffer pH 6.4, 0.05 mL, 0.1 M DTT (containing 1 mM ZnSO ₄ ) 05 mL, 0.05 mL of 50 mM ALA hydrochloride was added to make a total volume of 0.5 mL, this was maintained at 37 ° C. for 30 minutes, 0.5 mL of 1M trichloroacetic acid was added, the reaction was stopped, and the Ehrlich reagent was added to the 3000 rpm supernatant. After exactly 10 minutes, the absorbance at 553 nm, which is the characteristic absorption of the compound produced by the reaction of the Ehrlich reagent and PBG, was measured using a spectrophotometer (OD).

The calculation was performed as follows using the molecular extinction coefficient 61000 of the reaction product PBG obtained by the ALAD activity. An empty sample was used with a reaction time of 0 minutes (OD ₀ ).

ALAD activity = 1M x (OD-OD ₀ ) / 61000 x 2/1000 x 1 / mL of reaction sample x 1
= 32.8 × (OD-OD ₀ ) / reaction sample volume (mL) nmolPBG / mL / h

  The PBGD activity was measured as follows. After adding 0.38 mL of distilled water to 0.02 mL of whole blood of mice treated with heparin, 0.05 mL of 0.6 mM PBG (including 0.38 M Na-phosphate buffer pH 7.8) was added, Hold for 30 minutes. After stopping the reaction by adding 0.05 mL of 5M trichloroacetic acid (containing 0.8% iodine), the fluorescence intensity at an excitation wavelength of 405 nm and a fluorescence wavelength of 597 nm was measured with a centrifugal supernatant at 3000 rpm for 5 minutes. did.

  The calculation was carried out in proportion using a standard substance of uroporphyrinogen type 1 isomer obtained by PBGD activity.

That is, FU (Em = 597 nm fluorescence intensity) = 139 when the standard substance is 0.536 nmol URO / mL
Therefore, PBGD activity = 0.536 / 139 × 0.5 / 0.01 × 2 × FU / Ht

  The test was carried out with 5 male mice per section, and the values showed average values. In the section treated with ALA, it was confirmed that ALAD activity and PBGD activity were improved.

  As described above, it has been found that by ingesting ALA, the activity (ALAD activity, PBGD activity) of the heme synthesis pathway constituting the heme protein, which is an important factor of the respiratory electron transport system, is improved. Therefore, when this pathway is activated, it is considered that the citric acid circuit (TCA cycle) that performs energy metabolism in the animal body is activated and the motor function is improved.

Example 3
Mice preliminarily raised for one week (35 to 45 weeks old, BALB / cAJc1) were ingested with 10 mg of ALA hydrochloride per kg of mouse body weight once a day for 7 consecutive days. ALA hydrochloride was adjusted to a concentration of 0.5 g / mL with distilled water and orally administered to mice. Before and after the test, it was put in a rotary momentum measuring device (rotary rod: diameter 200 mm × width 50 mm, breeding rod: W90 mm × D220 mm × H90 mm, manufactured by Shinano Manufacturing Co., Ltd.), and the number of rotations for 16 hours was measured. The test was carried out with one mouse per rotational momentum, and was carried out on female mice with 5 untreated animals and 5 ALA-treated animals as one group, and the values showed average values. In the section where ALA was treated, it was confirmed that the amount of rotation was large and the exercise ability was improved.

Example 4
Introduce 120 ddY-N mice (60 males and 60 females) produced by Nippon Medical Science Animal Materials Co., Ltd. at about 4 weeks of age, and conduct a one-week quarantine to ensure no abnormal health It confirmed and used for the test. The test group is a control group in which water for injection is administered by oral gavage using a gastric sonde at a rate of 10 mL per kg body weight of the test mice for 28 days, and ALA hydrochloride is 5 mg per kg body weight of the test mice, 10 mg. And a total of 4 groups of 3 test groups administered similarly in the ratio of 25 mg were set. The test mice were divided into 12 groups with 5 groups of 1 group for each male and female so that the average body weight of each group was almost equal, and 3 groups of male and female were assigned to each group for 28 days. Raised. The test mice were reared for each group using a stainless steel five-unit cage installed in a rearing room set at a room temperature of 23.0 ± 2.0 ° C. and an irradiation time of 12 hours / day. The weight gain was calculated by measuring the body weight of each solid at weekly intervals from the start of the test.

As a result, as shown in the growth curve during the test period (average of males and females, FIG. 1), the 10 mg / kg administration group showed growth superior to the other 3 groups. Since the function was improved and the effect of weight gain was also observed, it was found that it was useful as a health function improver.
In the ALA addition group, no abnormality was observed in the health condition.

Example 5
14 LW / D seed pigs produced on the same day at the pig farm (7 castrates, 7 females each) were introduced in 3 portions and pre-raised for 9-12 days to confirm that there was no abnormal health After that, each time, 12 animals (castrated, 6 females each) were selected and used for the test. The test plots were set for a total of three plots: a control plot for supplying a control feed (Table 4) without addition of ALA hydrochloride, and a test plot for feeding a feed supplemented with 10 ppm and 50 ppm of ALA hydrochloride. The test pigs were divided into 3 groups of 4 (castrated, 2 females each) so that the weight distribution was almost uniform, and 1 group was assigned to each group and raised for 6 weeks. The test pig house was an open-type pig house in which 14 x 1.8-2.7m concrete floor pig bunches were juxtaposed, and grouped using 3 pig bunches adjacent to each block. The floor was made from rice straw. A heat insulation box was installed in each pig chamber until 3 weeks after the start of the test. Feed and drinking water were provided constantly. The weight gain was calculated by measuring the body weight of each solid at weekly intervals from the start of the test.
As a result, as shown by the growth curve during the test period (castration, female average, FIG. 2), 10 ppm and 50 ppm added group showed growth superior to the control group. Since it improved and the weight gain effect was also recognized, it turned out that it is useful as a health function improvement agent.
In the ALA addition group, no abnormality was observed in the health condition.

Example 6
A total of 300 broilers, 150 chicks (chunky) each, were introduced. We removed chicks (weakness and dwarf) in which abnormalities were observed after the introduction, wore wings for individual identification, and weighed each individual. Each male and female was divided into 3 groups (more than 45 birds per group) according to body weight, and 15 birds were randomly assigned to each group within each group. A tick guard installed in a closed barn housed 15 males and 15 females (30 in total) as a group, and an infrared ray lamp for animals was installed and kept warm. Chick guard expanded with the development of chicks. Feed and drinking water were constantly fed. The test group consisted of a control feed without ALA hydrochloride (standard feed for test SDB No. 1 from the beginning to 3 weeks of age, standard feed for test SDB No. 2 from 3 weeks to 7 weeks of age (all in Japan) A total of 3 groups: a control group that supplies a feed containing 10 ppm and 50 ppm of ALA hydrochloride, and an ALA-10 ppm addition group and an ALA-50 ppm addition group that supply a feed containing 10 ppm and 50 ppm. Was set, and each group had 3 repeat sections. Table 6 shows the number of test feathers in each test group. The test period was 7 weeks (7 weeks of age) from the beginning (start of feeding the supplemented feed), and the total body weight by sex was measured for each repeated section at the time of initial birth and every week thereafter. In addition, about 2 mL of blood was collected from the brachial vein (ulcer lateral vein) of 18 birds (3 males and 3 females / repeated) at 3 weeks and 7 weeks of age, about 1.5 mL of which was collected from heparin-lithium. After anticoagulation treatment with salt, plasma is separated, LDH, GOT (AST), γ-GTP, ALP, total protein, albumin, globulin, total cholesterol, neutral fat, blood sugar, uric acid, total bilirubin, uric acid The items of creatinine, calcium and inorganic phosphorus were examined. As a result, as shown in Table 7, the body weight during the test period (average of males and females) was not different among the test groups in the body weight from the beginning to 3 weeks of age, but the body weight after 3 weeks of age. Became larger than the control group in the ALA-10 ppm added group and the ALA-50 ppm added group. Moreover, in the results of the blood test, as shown in Table 8, γ-GTP (gamma glutamyl transpeptidase) was found to be decreased from the control group in the ALA-10 ppm added group and the ALA-50 ppm added group, It was found that ALA has a liver function improving effect and is useful as a health function improving agent.
In addition, in the ALA addition group, no abnormality was observed in the general state during the test period, and no abnormality considered to be due to the addition was also observed in the growth rate and autopsy findings.

It is a figure which shows the growth curve of a mouse | mouth. It is a figure which shows the growth curve of a pig farm.

Claims (8)

  A health function improving agent comprising δ-amino acid, a derivative thereof or a salt thereof as an active ingredient.   The health function improving agent according to claim 1, wherein the health function is improved by improving the motor function.   The health function improving agent according to claim 1, wherein the health function is improved by improving the liver function. The δ-amino acid, its derivative or its salt is represented by the following formula (1)

(Wherein R ¹ represents a hydrogen atom or an acyl group, and R ² represents a hydrogen atom or a hydrocarbon group which may have a substituent)
The health function improving agent according to any one of claims 1 to 3, which is a compound represented by the formula:   Furthermore, the health function improving agent of any one of Claims 1-4 which contains a mineral.   The health function improving agent according to claim 5, wherein the mineral is iron or copper.   The health function improving agent according to any one of claims 1 to 6, which is an agent for oral, injection, tube, or enteral ingestion.   The health function improving agent according to any one of claims 1 to 7, which is for ingesting 0.001 to 1000 mg of δ-amino acid, a derivative thereof or a salt thereof per kg of body weight per day.

Images